Affimed NV
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, … Read more
Affimed NV (AFMD) - Total Liabilities
Latest total liabilities as of September 2024: $22.76 Million USD
Based on the latest financial reports, Affimed NV (AFMD) has total liabilities worth $22.76 Million USD as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Affimed NV - Total Liabilities Trend (2012–2023)
This chart illustrates how Affimed NV's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Affimed NV Competitors by Total Liabilities
The table below lists competitors of Affimed NV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Export Inv
TA:EXPO
|
Israel | ILA20.83 Billion |
|
Vivesto AB
ST:VIVE
|
Sweden | Skr16.44 Million |
|
Reliv International Inc
PINK:RELV
|
USA | $4.71 Million |
|
Asiaplast Industries Tbk
JK:APLI
|
Indonesia | Rp127.79 Billion |
|
Brite Tech Bhd
KLSE:0011
|
Malaysia | RM70.81 Million |
|
Surefire Resources NL
AU:SRN
|
Australia | AU$10.04 Million |
|
Pipe Works L. Girakian Profil S.A.
AT:PROFK
|
Greece | €22.94 Million |
Liability Composition Analysis (2012–2023)
This chart breaks down Affimed NV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Affimed NV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Affimed NV (2012–2023)
The table below shows the annual total liabilities of Affimed NV from 2012 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $39.35 Million | -17.33% |
| 2022-12-31 | $47.60 Million | -46.63% |
| 2021-12-31 | $89.18 Million | -14.02% |
| 2020-12-31 | $103.73 Million | +40.76% |
| 2019-12-31 | $73.69 Million | -3.09% |
| 2018-12-31 | $76.05 Million | +556.75% |
| 2017-12-31 | $11.58 Million | +15.93% |
| 2016-12-31 | $9.99 Million | -17.10% |
| 2015-12-31 | $12.05 Million | +19.12% |
| 2014-12-31 | $10.11 Million | -90.43% |
| 2013-12-31 | $105.72 Million | +31.64% |
| 2012-12-31 | $80.31 Million | -- |